The most common treatments for cancer are radiation and chemotherapy. However they have side effects and also damage healthy tissues. Moreover, their effectiveness is limited when the cancer has spread through out the body. Researchers at the Niels Bohr Institute are therefore working to develop a gentler treatment that 'tricks' the cancer cells, which would absorb a cytotoxin and therefore be destroyed, while healthy cells would remain unaffected.

Walter Reed Army Institute of Research (WRAIR) researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model. A vaccine to prevent infection and disease caused by P. vivax is critical to reduce sickness and mortality from vivax malaria, a common cause of malaria among deployed service members.

Linde Healthcare, a global business of The Linde Group, has announced the new beneficiaries of its REALfund initiative, a programme supporting ideas and projects with the potential to improve patient outcomes and health economics across the wide field of respiratory medicine.

A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today's online edition of the journal Science. Importantly, the antibody, known as mAb114, was effective even when given five days after exposure to Ebola virus, suggesting that it could hold promise as a potential treatment for human cases of EVD.

To help healthcare professionals, medical researchers and the public understand the ongoing outbreak of the Zika virus, Elsevier has created a Zika Virus Resource Center on Elsevier's public news and information website. In addition, The Lancet, one of Elsevier's top medical journals, has created a Zika virus resource centre on its website,

Australian researchers have resolved a mystery about how a promising new class of anti-cancer drugs, called nutlins, work - paving the way for improving the future of cancer treatment. Nutlins, which are in early clinical trials for treating blood cancers, sparked interest worldwide for their ability to stop cancer growth by activating the body's natural cancer-suppressing

Less than 40% of the results of clinical trials conducted at leading academic medical centers were shared within two years of completion, Yale School of Medicine researchers report in a new study published in the current issue of the British Medical Journal.